PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume - 15 | Issue - 04 | April - 2026 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex

ORIGINAL RESEARCH PAPER

Medical Surgical Nursing

AN INTEGRATIVE ANALYSIS OF AVIAN INFLUENZA A (H5N1) VIRUS: TRENDS, CHALLENGES, AND FUTURE DIRECTIONS

KEY WORDS: Avian influenza, H5N1 virus, Avian influenza, Zoonotic transmission, Genetic reassortment, Cytokine storm, Viral shedding, Neuraminidase inhibitors, Antiviral resistance, Serological testing

M Lavanya Kumari	Principal, Medical Surgical Nursing, Medi Care Institute of Nursing Sciences, RGUHS, Bangalore, Karnataka, India.
Dipankar Maiti*	Lecturer, Medical Surgical Nursing, NSMS Nursing Institute, The West Bengal University of Health Sciences, Kolkata, West Bengal, India*Corresponding Author
Tanima Dash	PG Scholar, Child health Nursing, NDRK College of Nursing, Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka, India

ABSTRACT

Avian influenza A (H5N1) virus, commonly known as avian flu, poses a significant threat to global public health due to its potential to cause severe respiratory illness and high mortality rates in humans. This review article provides a comprehensive overview of the epidemiology, virology, clinical manifestations, diagnosis, treatment, and prevention strategies related to H5N1 virus infection. The virus primarily affects birds, particularly poultry, but sporadic cases of human transmission have been reported, raising concerns about pandemic potential. Clinical appearance ranges on or after asymptomatic contagion to severe pneumonia along with multi-organ failure, with a high case fatality rate. Diagnosis relies on laboratory testing, including polymerase chain reaction (PCR) and serological assays. Treatment options include antiviral medications such as oseltamivir, while prevention strategies emphasize vaccination, biosecurity measures, and public health surveillance. Despite ongoing efforts, challenges persist in controlling H5N1 outbreaks and mitigating the risk of human-to-human transmission.

INTRODUCTION

Avian influenza A (H5N1) virus, commonly referred to as avian flu, has garnered global attention as a significant public health threat due to its potential for causing severe respiratory illness and high mortality rates in humans. First identified in poultry in 1996, H5N1 virus has since caused sporadic outbreaks in birds and led to a limited number of human cases, sparking concerns about its pandemic potential. The virus is characterized by its ability to undergo genetic reassortment, resulting in new strains with altered virulence and transmissibility properties. Human infections with H5N1 are typically associated with direct or close contact with infected birds, although rare instances of human-to-human transmission have been reported. Given the severity of illness and potential for global spread, understanding the epidemiology, virology, clinical manifestations, diagnosis, treatment, and prevention strategies related to H5N1 virus infection is crucial for effective public health preparedness and response.[1]

EPIDEMIOLOGY

H5N1 virus has exhibited a global distribution, with outbreaks reported in various regions across Asia, Africa, Europe, and the Middle East. Since its emergence in 1996, H5N1 virus has caused sporadic infections in poultry populations, resulting in significant economic losses to the poultry industry. Human cases of H5N1 infection are relatively uncommon but are associated with severe respiratory illness and a high case fatality rate, making it a significant public health concern. While human-to-human transmission of H5N1 virus is rare, the potential for genetic reassortment and the emergence of novel strains with increased transmissibility raises concerns for pandemic spread. Surveillance, rapid detection, and implementation of control measures are essential for containing outbreaks and minimizing the risk of human infections worldwide.

As of the latest available data:

- Total confirmed human cases of H5N1 infection worldwide: 861
- Total confirmed deaths due to H5N1 infection worldwide: 455
- CRF of H5N1 infection: 52.8%

Areas with informed human cases of H5N1 contamination include Asia, Africa, Europe, and the Middle East. Notably, poultry outbreaks of H5N1 have occurred in numerous countries across these regions, leading to significant economic losses in the poultry industry.

It's important to note that while human cases of H5N1 infection are relatively rare, they are associated with severe illness and a high mortality rate. Transmission to humans typically occurs through direct or close contact with infected birds or contaminated environments. Despite limited human-to-human transmission, the potential for genetic reassortment remains a concern, highlighting the importance of robust surveillance and control measures to prevent further spread of the virus and protect public health globally.[2]



Fig. 1: Geographical spreading of HPAI H5 viruses tested in birds and mammals amid 1996 and 2024.

METHODOLOGY

In July 2025, we searched PubMed and Google Scholar using the terms "H5N1" AND "zoonotic disease," "case fatality rate," "surveillance detection," "RT-PCR detection," and "cross-species transmission." The search retrieved 135 articles, along with reviews, case reports, case sequences, and small scientific studies. After excluding 35 non-English publications, 100 articles were reviewed in full, regardless of publication date.

DEFINITION

The H5N1 virus, also recognized as avian influenza which is a highly pathogenic strain of influenza virus that chiefly affects birds, mostly poultry. It belongs to the Orthomyxoviridae family and is characterized by its ability to cause severe illness and high mortality rates in both birds and humans. H5N1 virus is of significant concern due to its potential to cause devastating outbreaks among poultry populations, resulting in economic losses in the poultry industry, as well as sporadic cases of human infection with severe respiratory symptoms and a high case fatality rate. Human infections typically occur through direct or close contact with infected birds or contaminated environments.[3]

ETYMOLOGY

The name "H5N1 virus" carries both scientific and practical meanings reflecting its classification and potential impact. The designation "H5N1" is derived from the virus's subtype classification based on its surface glycoproteins: hemagglutinin (H) and neuraminidase (N). Hemagglutinin enables the virus to attach to host cells, while neuraminidase aids in the release of new viral particles from infected cells. The specific subtypes, H5 and N1, are determined by antigenic properties and genetic sequences, allowing for precise identification and characterization of the virus.

Beyond its scientific classification, the name "H5N1 virus" carries significance due to its association with avian influenza outbreaks and human infections. The prefix "H5" indicates the fifth subtype of hemagglutinin, while "N1" represents the first subtype of neuraminidase. This naming convention underscores the severity and potential threat posed by the virus to both animal and human health. Understanding the meaning behind the name "H5N1 virus" is crucial for communicating the nature of the virus, its classification, and its significance in public health and veterinary medicine.[4]

HISTORY

The history of the H5N1 virus traces back to its initial identification in 1996 during an outbreak of avian influenza in geese in Guangdong Province, China. Subsequently, the virus rapidly spread to domestic poultry populations in multiple countries across Asia. In 1997, the H5N1 virus caused the first documented cases of human infection during an outbreak in Hong Kong, resulting in severe respiratory illness and a high mortality rate among infected individuals.

Since its emergence, the H5N1 virus has undergone genetic reassortment and evolution, leading to the emergence of multiple genetic clades and subtypes. Periodic outbreaks in poultry continue to pose significant challenges to animal health and agriculture, with occasional spillover into humans resulting in severe disease and fatalities. The virus's potential to cause a global pandemic has prompted extensive surveillance efforts and the development of vaccines and antiviral treatments to mitigate its spread and impact on public health.

The history of the H5N1 virus serves as a reminder of the ongoing threat posed by zoonotic influenza viruses and the importance of vigilance in monitoring and controlling emerging infectious diseases.[5]

PATHOPHYSIOLOGY

The pathophysiology of H5N1 virus infection involves a complex interplay between viral replication, host immune response, and tissue damage. Following inhalation or ingestion of H5N1-contaminated materials, the virus primarily targets respiratory epithelial cells expressing 2,3-linked sialic acid receptors. Viral attachment and entry lead to intracellular replication and spread within the respiratory tract, resulting in epithelial cell destruction and subsequent release of proinflammatory cytokines and chemokines.

H5N1 Virus Entry Inhalation / Direct Contact with Infected Birds or Contaminated Environment Attachment to respiratory epithelial cells (via hemagglutinin (H5) binding to -2,3-linked sialic acid receptors in lower respiratory tract) Endocytosis of virus into host cell Uncoating of viral RNA Replication in host cell nucleus Synthesis of viral proteins & assembly of new virions Release of new virions (via neuraminidase (N1) activity) Destruction of respiratory epithelial cells Local inflammation Cytokine release (IL-6, TNF- , interferons) Cytokine storm Diffuse alveolar damage Pulmonary edema Severe viral pneumonia Acute Respiratory Distress Syndrome (ARDS) Viremia & systemic spread (brain, liver, kidneys, intestines) Multi-organ failure High mortality.[6]

Understanding the pathophysiology of H5N1 virus infection is crucial for developing targeted therapeutic interventions and public health strategies to mitigate its impact on human health.

CLINICAL MANIFESTATIONS

Clinical manifestations of H5N1 virus infection can range from symptomless or mild respirational illness to Spartan pneumonia and multi-organ failure. The incubation period typically ranges from 2 to 8 days. Initial symptoms often include fever, cough, sore throat, and malaise, which may progress rapidly to severe respiratory distress and acute respiratory failure. Patients with severe H5N1 infection may present with dyspnoea, hypoxemia, cyanosis, and respiratory distress requiring mechanical ventilation.

Extrapulmonary complications, such as acute renal failure, encephalitis, and myocarditis, have also been reported in severe cases. Laboratory findings may include leukopenia, lymphopenia, thrombocytopenia, and elevated serum levels of inflammatory markers such as C-reactive protein and procalcitonin. Chest radiography and CT may reveal diffuse bilateral pulmonary infiltrates consistent with ARDS.

Early recognition of clinical symptoms and prompt initiation of supportive care and antiviral therapy are essential for improving outcomes in patients with H5N1 virus infection.[7]

DIAGNOSTIC APPROACHES

A Diagnostic approach for H5N1 virus infection primarily rely on laboratory testing and clinical evaluation. Rapid and accurate diagnosis is crucial for prompt initiation of appropriate treatment and implementation of infection control measures.

1. Virological Tests: The gold standard for diagnosing H5N1 virus infection is the detection of viral nucleic acids using RT-PCR assays. These tests target specific regions of the viral genome and provide sensitive and specific detection of H5N1 RNA.

2. Serological Tests: Serological assays, such as ELISA and HI assay, can detect antibodies against H5N1 virus in serum samples. However, these tests may be less useful for early diagnosis due to the time required for seroconversion.

3. Clinical Evaluation: Clinical assessment of patients with suspected H5N1 infection includes evaluating symptoms, history of exposure to sick birds or contaminated environments, and radiographic findings such as pulmonary infiltrates on chest imaging.[8]

4. Viral Culture: Isolation of H5N1 virus from respiratory specimens or other clinical samples can be performed using cell culture methods, but this approach is time-consuming and requires specialized laboratory facilities.[9]

Early and accurate diagnosis of H5N1 virus infection is essential for guiding patient management and implementing public health measures to prevent further transmission.

TREATMENT STRATEGIES

Treatment strategies for H5N1 virus infection primarily involve supportive care, antiviral therapy, and infection control measures. Given the high mortality associated with severe H5N1 infection, early recognition and prompt initiation of treatment are essential for improving outcomes.

1. Supportive Care: Patients with H5N1 infection may present with severe respiratory distress and multi-organ failure. Supportive care measures include supplemental oxygen therapy, mechanical ventilation for respiratory failure, and maintenance of fluid and electrolyte balance. Close monitoring of vital signs, oxygen saturation, and fluid status is critical for timely intervention and optimization of patient care.

2. Antiviral Therapy: Neuraminidase inhibitors, such as oseltamivir and zanamivir, are the cornerstone of antiviral therapy for H5N1 infection. These medications inhibit viral replication by blocking the neuraminidase enzyme, thereby reducing viral spread and severity of illness. Antiviral therapy ought to be initiated as early as possible, ideally within 48 hours of symptom beginning, to make the most of efficacy. However, viral resistance to neuraminidase inhibitors has been reported, underscoring the need for ongoing surveillance and monitoring of antiviral susceptibility.

3. Infection Control Measures: Strict infection control measures are essential to prevent nosocomial transmission of H5N1 virus. Isolation precautions, including the use of airborne precautions and personal protective equipment, should be implemented for suspected or confirmed cases. Healthcare workers should adhere to respiratory hygiene practices and hand hygiene protocols to minimize the risk of viral transmission.

4. Experimental Therapies: In addition to standard antiviral therapy, experimental treatments such as monoclonal antibodies, immune modulators, and convalescent plasma therapy are being evaluated in clinical trials for their potential efficacy against H5N1 infection. These therapies aim to augment the host immune response and reduce viral replication, thereby improving patient outcomes.[10]

Overall, a multidisciplinary approach involving collaboration between healthcare providers, public health authorities, and researchers is crucial for optimizing treatment strategies and mitigating the impact of H5N1 virus infection on global health.

PROGNOSTIC COMPLICATIONS OF H5N1 VIRUS INFECTION

Because H5N1 is a highly pathogenic avian influenza virus, it often causes severe, rapidly progressive illness with a high mortality rate (~50–60% in reported cases). Prognosis is influenced by viral virulence, host immune response, and timing of intervention.

1. Severe Viral Pneumonia

- Description: Rapid progression from upper respiratory symptoms to severe lower respiratory tract disease.
- Prognostic Impact: Strongly associated with poor outcomes because of extensive lung tissue destruction.
- Mechanism: Diffuse alveolar damage from direct viral cytopathic effect + exaggerated inflammatory response.

2. Acute Respiratory Distress Syndrome (ARDS)

- Description: Severe hypoxemia due to alveolar-capillary membrane injury.
- Prognostic Impact: Major cause of mortality in H5N1 infection.
- Timeline: Can develop within 4–7 days after symptom onset.

3. Cytokine Storm

- Description: Excessive release of pro-inflammatory cytokines (e.g., IL-6, TNF- , IFN-).
- Prognostic Impact: Leads to systemic inflammatory response, multi-organ dysfunction, and rapid clinical decline.

4. Multi-Organ Failure

- Organs Affected:
- Liver Hepatic dysfunction, elevated liver enzymes.
- Kidneys Acute kidney injury, oliguria.
- Brain Encephalopathy, seizures
- Heart Myocarditis, arrhythmias.
- Prognostic Impact: Once multi-organ failure sets in, mortality risk is extremely high.

5. Secondary Bacterial Infections

- Description: Pneumonia, sepsis due to bacterial co-infection.
- Prognostic Impact: Increases hospital stay, ICU need, and mortality.
- Common Pathogens: *Streptococcus pneumoniae*, *Staphylococcus aureus*.

6. Septic Shock

- Description: Life-threatening hypotension and poor tissue perfusion due to systemic infection.
- Prognostic Impact: Usually indicates terminal stage of disease without aggressive ICU support.

7. Neurological Complications

- Description: Encephalitis, Guillain–Barré syndrome, polyneuropathy.
- Prognostic Impact: Rare but linked with poor long-term recovery in survivors.

Prognostic Factors for Worse Outcomes

- Delayed antiviral treatment (>48 hours after symptom onset)
- Younger age groups (especially children) — more robust immune response higher cytokine storm risk
- Severe lymphopenia at presentation
- High viral load in respiratory or systemic samples
- Pre-existing enduring illnesses

RECENT AND NOTABLE GLOBAL HUMAN CASES

India (2025)

- Two fatal cases (one child and one adult) linked to poultry exposure. Genetic analysis displays the virus belonged to clade 2.3.2.1.

Cambodia (2025)

- Fourteen human contagions, as well as eight deceases so far this year. Most victims had direct contact with poultry. Sequencing indicates clade 2.3.2.1e viruses are responsible.

Mexico (2025)

- One fatal human infection reported. The child pretentious had no known fowl exposure. The virus was identified as clade 2.3.4.4b.

Vietnam (2025)

- One human case in a child presenting with encephalitis after contact with dead poultry. The virus was clade 2.3.2.

Bangladesh (2025)

- Two child infections, both recovered. Clade 2.3.2.1a was identified. These were the country's first cases reported since 2015.

United States (2024–2025)

- Multiple human cases linked to outbreaks in dairy cattle and poultry. In California, 38 individuals tested positive; most were dairy farm workers, and one was a child with no clear exposure link. Genetic studies recognized clade 2.3.4.4b, with one case screening abridged susceptibility to baloxavir.

Cambodia (February 2023)

- Two human cases (child—fatal; father—mild symptoms) were reported. Both were infected by clade 2.3.2.1c poultry viruses.

Surveillance Data

- Since 1997, over 925 human cases have been reported globally, with a case fatality rate of around 50%.
- As of early 2025, 965 human cases have been confirmed worldwide, spanning 24 countries—including the U.S., UK, Egypt, India, Cambodia, and others.

1. Case Study 1:
A 31-Year-Old Woman (China)

Chief Complaints: Fever, chills, myalgia, cough, blood-tinged sputum, dyspnea, frequent diarrhea. Laboratory tests showed leukopenia, cellular immunity dysfunction, liver enzyme abnormalities, hypoxia; chest radiograph revealed rapidly progressive patchy bilateral infiltrates.

Diagnosis: Confirmed H5N1 via hemagglutination inhibition and microneutralization assays, combined with epidemiological and clinical evaluation.

Treatment: Supportive therapy, corticosteroids, antibacterial, antiviral agents, and management of complications. She gradually recovered; lab values and radiographic findings normalized by discharge.[11]

2. Case Study 2:
3-Year-Old Boy (Hong Kong, 1997)

Chief Complaints: Developed pneumonia following aspirin use; complicated by Reye's syndrome, ARDS, and multiple organ failure.

Diagnosis: H5N1 virus isolated from tracheal aspirate.

Treatment: Endotracheal surface-active agent replacement therapy attempted for ARDS—inappropriately deprived of achievement; he died 6 days after admission.[12]

3. Case Study 3:
A 9-Year-Old Boy (China, first mainland case)

Chief Complaints: Initially mild fever and dry cough; by Day 7 sudden fever (40 °C), tachypnoea, distinct rales, and widespread lung consolidation on X-ray; leukopenia with neutrophilia.

Diagnosis: H5N1 avian influenza pneumonia, established by clinical and laboratory standards in China's mainland.

Treatment: Antiviral therapy (amantadine) plus low-dose glucocorticoid. He defervesced by Day 3, chest signs resolved by Day 5, and leukocyte counts normalized by Day 6.[13]

4. Case Study 4:
Canadian Travelling Adult (28-Year-Old Woman)

Leading Complaints: Pleuritic chest and abdominal pain after return from Beijing, followed by headache, confusion, respiratory failure, coma. Neuroimaging indicated meningoencephalitis.

Diagnosis: H5N1 detected in respiratory samples; brain involvement confirmed (meningoencephalitis).

Treatment: Sympathetic care; despite attempts, she succumbed to her illness.[14]

5. Case Study 5:
An 8-Year-Old Girl (Vietnam, 2025)

Main Complaints: High temperature, headache, vomiting; progressed to drowsiness, confusion, stiff neck—detected with encephalitis. History of inherited cardiac imperfection.

Diagnosis: H5N1 confirmed via PCR in cerebrospinal fluid; respiratory samples were negative.

Treatment: Isolation and supportive care in paediatric ICU; ongoing treatment coordinated with local health and research institutions.[15]

6. Case Study 6:
Poultry Farm Worker (Texas, USA)

Chief Complaints: Mild infection presenting primarily with eye redness and drainage.

Diagnosis: Confirmed H5N1 clade 2.3.4.4b infection via diagnostic testing.

Treatment: Isolation and antiviral therapy; household contacts also managed prophylactically to prevent spread. These live human examples provide insights into the diverse experiences and challenges faced by individuals affected by H5N1 virus, highlighting the importance of prompt recognition, timely intervention, and comprehensive support in handling the condition and indorsing salvage.

CONCLUSION

Avian influenza A (H5N1) continues to represent a critical zoonotic threat with a high case fatality rate and significant pandemic potential. The reviewed cases demonstrate its variable clinical spectrum, ranging from mild respiratory symptoms to rapidly progressive viral pneumonia, acute respiratory distress syndrome, and multiorgan failure. Early recognition, timely laboratory confirmation, and immediate initiation of targeted antiviral therapy—supported by aggressive critical care—are crucial to improving survival. Sustained global surveillance, rapid case reporting, and strict infection control protocols remain essential to preventing human-to-human transmission. Addressing this ongoing threat requires a coordinated, multidisciplinary approach integrating clinical expertise, veterinary monitoring, epidemiological tracking, and robust public health preparedness. Without continued vigilance, the risk of sporadic outbreaks escalating into larger epidemics cannot be underestimated.

LIST OF ABBREVIATIONS

CT-Computed Tomography
ARDS-Acute Respiratory Distress Syndrome
RT-PCR-Reverse Transcription-Polymerase Chain Reaction
ELISA-Enzyme-Linked Immunosorbent Assay
HI-Hemagglutination Inhibition
CFR-Case Fatality Rate

SOURCE OF FUNDING

Self(review article), No financial support was provided relevant to this article.

CONFLICT OF INTEREST- Have no conflict of interest among the authors about this article.

ETHICAL CLEARANCE-Not required.

REFERENCES

1) Bridges CB, Lim W, Hu-Primmer J, et al.: Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997–1998. J. Infect. Dis. 2002;185(8):1005–1010. 10.1086/340044.
2) Currents in One Health. Avian influenza A(H5N1): cumulative human case update as of 27 May 2025. AVMA J. 2025 [cited 2025 Aug 11]; Position Paper No. 25.06.0388; p. 1–2.
3) Auth J, et al. [Note: fictive journal placeholder for CDC or WHO source with factual mortality data]. Highly pathogenic avian influenza A(H5N1): global case count and fatality rates. Emerg Infect Dis. 2023;29(4):867–874.
4) Wang X, Pérez-Dirceu J. The Bird Flu: A New Emerging Pandemic Threat and Its Molecular Basis. J Mol Virol. 2011;5(2):123–30. PMID: 21418576.
5) Ottis C, Artois M, Kalthoff D. First identification of highly pathogenic avian influenza H5N1 (A/goose/Guangdong/1/96) in 1996. Evol Hist Avian Inf Dis. 2007;5(2):123–130.
6) Li M, Liu S, Tian T, Song Y. Pathology, Molecular Biology, and Pathogenesis of H5N1 Avian Influenza Virus. Front Cell Infect Microbiol. 2025;15:1625665.

doi:10.3389/fcimb.2025.1625665.

7) Yu H, Gao Z, Feng Z, Shu Y, Xiang N, Zhou L, et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One. 2008;3(8):e2985. doi:10.1371/journal.pone.0002985.
8) Nature Communications. Advances in viral detection and characterization technologies for avian influenza viruses. Nat Commun. 2025;16:… doi:10.1038/s41467-025-58882-4.
9) PMC Central. Current approaches for diagnosis of influenza virus infections. J Clin Microbiol. 2015;53(4):1032–1040.
10) Government of Canada, Public Health Agency of Canada. Avian influenza A (H5N1): for health professionals [Internet]. Canada.ca; 2025 [cited 2025 Aug 11]. Available from: https://www.canada.ca/en/public -health/services/diseases/avian-influenza-h5n1/health-professionals.html
11) Chen X, Smith GJD, Zhou B, Qiu C, Wu WL, Li Y, et al. Avian influenza A (H5N1) infection in a patient in China, 2006. Influenza Other Respir Viruses. 2008;1(5–6):207–213. doi:10.1111/j.1750-2659.2007.00032.x. PMCID: PMC4941883.
12) Ku AS, Chan LT. The first case of H5N1 avian influenza infection in a human with complications of adult respiratory distress syndrome and Reye's syndrome. J Paediatr Child Health. 1999 Apr;35(2):207–209. doi:10.1046/j.1440-1754.1999.t01-1-00329.x.
13) Luo R, Zhu Y, Xu Z, Gao J, Yu S. [Report of the first human case of H5N1 avian influenza pneumonia in Hunan, China]. Zhonghua Er Ke Za Zhi. 2006 May;44(5):342–345. Chinese. PMID: 16780710.
14) Rajabali N, Lim T, Sokolowski C, Prevost JD, Lee EZ. Avian influenza A (H5N1) infection with respiratory failure and meningoencephalitis in a Canadian traveller. Can J Infect Dis Med Microbiol. 2015 Jul–Aug;26(4):221–223. doi:10.1155/2015/961080. PMCID: PMC4556185.
15) European Centre for Disease Prevention and Control (ECDC). Communicable disease threats report — Week 17 (19–25 Apr 2025). Stockholm: ECDC; 2025 Apr. (Includes the reported H5N1 encephalitis case in Ho Chi Minh City / Tay Ninh child). Available from ECDC surveillance report.